Benchling
Benchling makes software biotech labs use to track experiments and manage lab data.
On the record
Checkpoint: Benchling's AI Scientist tool moves from waitlist to general availability with real usage data
The call
Benchling still runs the daily lab work at most big biotechs, but its valuation hasn't been tested since 2021 and AI-first drug discovery is an open question mark.
Benchling makes software that biotech researchers use to record experiments, manage lab data, and track biological samples in one place. It is hard to replace because 1,300 customers and 200,000 scientists depend on it daily, and switching to a competitor like Veeva or Dotmatics would be costly and risky under strict regulatory rules. However, new AI tools that design proteins and run experiments in computers instead of wet labs could eventually make Benchling's notebook-focused approach less central to how drug discovery actually works, especially if those AI tools get built into new software from scratch rather than bolted onto old lab systems. The big question is whether Benchling ships and sells its own AI scientist tool by late 2026 with real paying customers, or whether it stays stuck as an older-generation platform while AI-first biology companies move the needle elsewhere.
Why
01
AI pressure: In-silico biology tools like AlphaFold, Chai Discovery, Latent Labs. If drug discovery moves from wet labs to computer simulation, fewer scientists need Benchling's lab notebook at all. Could AI do the core job? Only partly.
02
Bigger players: Veeva Systems. Veeva dominates biotech's regulatory and clinical software and could push into R&D lab tools where Benchling now leads. Could a giant copy it? Probably.
03
What protects it. Over 1,300 biotech customers and 200,000 scientists already run daily lab work through Benchling, and switching a validated lab system is slow and risky.
What would change this call
Benchling's 'AI Scientist' exits waitlist with published adoption or customer usage metrics by Q4 2026. Would confirm the AI moat is real rather than aspirational marketing.
A new primary funding round or secondary valuation event is confirmed after the stale Nov-2021 $6.1B mark. Would show whether investors still value Benchling at or above its 2021 peak.
Headcount trends over next 2-3 quarters after 2025's 98.5% jump in job postings. Would show whether hiring rebounds or attrition (down 24% since 2023) continues.
A new primary funding round or secondary valuation event is confirmed after the stale Nov-2021 $6.1B mark. Would show whether investors still value Benchling at or above its 2021 peak.
Headcount trends over next 2-3 quarters after 2025's 98.5% jump in job postings. Would show whether hiring rebounds or attrition (down 24% since 2023) continues.
Key numbers
- 1,300+ biotech customers, 200,000+ scientists
- Revenue growth slowed to about 27% YoY
- Headcount down 24%, from 1,032 to 787 staff
Named risks
- No primary funding round confirmed since November 2021, leaving the $6.1B valuation unrefunded for over four years.
- Revenue growth decelerated from 175% to 27% YoY, signaling market maturation.
- Headcount down 23.7% since 2023 despite two layoff rounds (April 2023, January 2025).
- AI Scientist product remains on a waitlist as of April 2026, not yet in production with verified customer adoption.
- In-silico-first generative biology pipelines could bypass wet-lab-centric ELN workflows over time.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Dotmatics | contesting | Named as closest direct ELN/LIMS rival in February 2026 comparison content |
| Sapio Sciences | contesting | Head-to-head LIMS comparisons published February 2026 |
| Veeva Systems | gaining on | Adjacent incumbent in regulated-quality workflows, not yet in core R&D discovery, as of June 2026 |
| Generative biology tools (AlphaFold-class, Chai Discovery, Latent Labs) | losing to | CEO warned in-silico-first pipelines could de-emphasize wet-lab ELN workflows, April 2026 |
Questions people ask
- Is Benchling profitable in 2026?
- No public profitability figures exist. Benchling is estimated at around $210M ARR by May 2024 with 27% YoY growth, per Sacra, but as a private company it discloses no audited profit or loss data, so profitability status is unconfirmed as of mid-2026.
- Has Benchling had layoffs?
- Yes. Benchling cut 74 employees, 9% of its workforce, in April 2023, and Endpoints News reported additional layoffs in January 2025. Headcount fell from about 1,032 employees in 2023 to 787 by December 2025, per Revelio Labs, a roughly 24% decline.
- Could AI replace Benchling?
- Unlikely soon. Benchling holds proprietary structured R&D data across 1,300+ biotech customers and 200,000+ scientists, protected by compliance requirements and switching costs. Instead it is integrating AI via Anthropic (October 2025) and its own AI Scientist waitlist, launched April 2026, positioning itself as an AI platform rather than a target for replacement.
- Who is Benchling's biggest competitor?
- Dotmatics and Sapio Sciences are the closest direct ELN/LIMS rivals, alongside LabWare, LabVantage, and STARLIMS. Veeva Systems is an adjacent incumbent in regulated-quality workflows but has not yet entered core R&D discovery, per a February 2026 competitor comparison.
- What is Benchling's valuation and who owns it?
- Benchling is privately held, backed by investors including Benchmark, Thrive Capital, Lux Capital, and Altimeter Capital. Its last confirmed valuation was $6.1B from a $100M Series F round co-led by Altimeter and Franklin Templeton on November 18, 2021; no newer primary round has been publicly confirmed as of mid-2026.
- Is Benchling's growth slowing down?
- Yes. Benchling's year-over-year revenue growth decelerated sharply: from 175% in 2019 to 100% in 2020, 82% in 2021, 45% in 2022, and roughly 27% by May 2024 when ARR reached about $210M, according to Sacra's March 2026 estimate.
Timeline
- 2026-05-11Launched One-Click Ordering, Benchling Biologics GA, and AI Data Analysis skill at SynBioBeta
- 2026-04-23CEO published AI Scientist vision with public waitlist at benchling.com/ai
- 2025-10-20Partnered with Anthropic to embed agents into Claude's Life Sciences Ecosystem
- 2025-10-14Launched Benchling AI and Benchling Biologics at Benchtalk conference
- 2025-08-20Acquired AI teams behind ReSync Bio and Sphinx Bio
- 2025-01-29Additional layoffs reported at Benchling
- 2024-10-19Acquired PipeBio, a bioinformatics company for antibody discovery
- 2024-05-01Benchling ARR estimated to cross $200M, per Sacra
- 2023-04-24Laid off 74 employees, 9% of workforce
- 2021-11-18Raised $100M Series F co-led by Altimeter and Franklin Templeton at $6.1B valuation
Revision history
29 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Benchling Raises $100M in Series F Financing Co-Led by Altimeter and Franklin Templeton (2021-11-18)
- Benchling revenue, valuation & funding (2026-03-22)
- Benchling Accelerates AI Roadmap with ReSync Bio and Sphinx Bio (2025-08-20)
- Benchling Partners with Anthropic to Build a Bridge Between Science and AI (2025-10-20)
- Benchling Number of Employees 2026 (2026-06-29)
- Life sciences software company Benchling trims workforce by 9% (2023-04-24)
- Curie.Bio has a new $340M fund; Layoffs at Benchling, I-Mab (2025-01-29)
- Benchling acquires PipeBio to accelerate AI-powered antibody discovery (2024-10-19)
- Benchling Reveals the Next Chapter of R&D at Benchtalk 2025 (2025-10-14)
- Benchling Launches Three Products During SynBioBeta 2026 (2026-05-11)
- An AI Scientist that deserves the name (2026-04-23)
- Life sciences software startup Benchling lays off 9% of workforce (2023-04-21)